News
04-21-2011, 06:20 AM
Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.
More... (http://www.news-medical.net/news/20110421/Merrimack-initiates-dosing-in-MM-111-combination-Phase-1-study-in-advanced-HER2-positive-patients.aspx)
More... (http://www.news-medical.net/news/20110421/Merrimack-initiates-dosing-in-MM-111-combination-Phase-1-study-in-advanced-HER2-positive-patients.aspx)